Collagen secretion and maturation in osteogenesis imperfecta: Systematic review and meta-analysis.
Researchers characterize how bone disease collagen defects vary by genetic type, informing which patients benefit from new quality-focused therapies.
This SR+MA systematically characterizes how collagen I biosynthesis is disrupted at the secretion and maturation stages in osteogenesis imperfecta, quantifying defects across genetic subtypes. The genotype-phenotype correlation at the collagen level has practical implications for stratifying OI patients for emerging therapies targeting collagen quality rather than quantity.
What the study was
- Study design
- Systematic review and meta-analysis
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Bone Rep
Why it surfaced
OI is a high-unmet-need rare bone disease; gene therapy and collagen-targeting agents are in development; SR+MA provides genotype-phenotype mapping that will inform patient stratification for trials.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.